ANTIMICROBIAL RESISTANCE SOLUTIONS
WITH DR. JOHN H. REX
Latest Newsletters
Latest Government Action





















R&D Insight
Can you help?
Antimicrobial resistance poses a catastrophic threat. If we don’t act now, any one of us could go into hospital in 20 years for minor surgery and die because of an ordinary infection that can’t be treated by antibiotics. And routine operations like hip replacements or organ transplants could be deadly because of the risk of infection.
Dame Sally Davies Tweet


















Non-traditional antibiotics: A pipeline review and an analysis of key development challenges
New mechanisms for antibiotic reimbursement in the United States: CMS’s IPPS FY2020 Final Rule
New pipeline analysis: Cancer projects were funded 17x more than antibacterials during 2011-2020
Categories of resistance: MDR, XDR, PDR, UDR, and (new!) DTR
Push! Pull! Push! Pull! / Highlights from Davos 2018
Language matters: CRE vs. CPE; SDD vs. I; and MDR, XDR, PDR, UDR vs. DTR
How hard (and how) to Pull? Net value of Pull via a Transferrable Exclusivity Extension (TEE)
FDA analysis of 40-years of antibacterial development: Dheman et al.
Modeling the value of an effective antibiotic — Megiddo et al.
Draft EMA antibacterial guidance: Analysis
IDSA White Paper on developing narrow-spectrum antimicrobials + editorial by G. Drusano
FDA and EMA regulatory updates / Fireside chat during the 4th AMR Conference
The thoughtless person playing with penicillin treatment is morally responsible for the death of the man who succumbs to infection with the penicillin-resistant organism.
Alexander Fleming Tweet

The bipartisan PASTEUR Act is the strongest bill ever written to strengthen antibiotic development and use. It will fix our market failures, expand the pipeline for next generation antibiotics, and save lives. We can’t sit on our hands as this public health crisis arrives – we have to act now.
U.S. Senator Michael Bennet Tweet